Chronic rhinosinusitis Ear, Nose and Throat
Conditions
Interventions
The study will include patients diagnosed with CRS (chronic rhinosinusitis) based on the 2020 EPOS criteria. These patients will be divided into two phenotypic groups: CRSwNP (chronic rhinosinusitis w
Sponsors
Lithuanian University of Health Sciences, LSMU
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with CRS: 1. Based on the 2020 EPOS criteria, a CRS diagnosis was established, and the patient underwent endonasal sinus surgery. 2. Presence of two or more symptoms: nasal obstruction/difficulty breathing through the nose, nasal discharge/postnasal drip, and/or facial pain or pressure, and/or loss or reduction of the sense of smell. 3. Endoscopic findings (polyps, mucopurulent discharge in the middle nasal meatus, mucosal swelling—edema causing obstruction, primarily in the middle nasal meatus); changes visible in computed tomography scans (bony canal and ostiomeatal complex changes and/or sinus mucosal changes). Healthy (Control) Participants: 1. Individuals without CRS received treatment for conditions not related to CRS, such as skull base lesions, lacrimal sac or orbital issues, and nasal septum defects. General Criteria: 1. Individuals who are 18 or older and meet the criteria mentioned above. 2. Participants are willing to take part in the study voluntarily. 3. Individuals who have read and signed the informed consent form and the genetic testing consent form.
Exclusion criteria
Exclusion criteria: 1. Individuals under 18 years of age 2. Individuals for whom venous puncture is contraindicated or poses a risk of complications 3. Individuals who have not read or signed the informed consent form 4. Pregnant women 5. Individuals with autoimmune diseases 6. Individuals with diabetes mellitus 7. Individuals with chronic lung diseases, such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), or similar conditions 8. Individuals with Wegener's granulomatosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured on the day of surgery: 1. The concentrations of IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-17, IL-21, IL-22, IFN-?, and TNF-a (in pg/ml) will be measured in tissue and serum samples using the flow cytometry-based Luminex method, which allows simultaneous detection of all investigated marker concentrations. 2. Gene polymorphism analysis in blood samples will use allele-specific primers based on the competitive allele-specific PCR (KASP) reaction methodology. The polymerase chain reaction (PCR) method will be used to determine differences in the gene expression of miRNA in plasma, TGF-ß, and Wnt signaling pathways, extracellular matrix proteins, and their regulatory molecules in postoperative tissue samples. | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured on the day of surgery: 1. Complete blood count test 2. Histology of biopsy material 3. Citology tests 4. Assessing the quality of life using the SNOT-22 questionnaire | — |
Countries
Lithuania
Contacts
Public ContactZygimantas;Ieva Vaitkus;Janulaityte
;
Outcome results
None listed